Lumbar interbody fusion after treatment with recombinant human bone morphogenetic protein-2 added to poly(L-lactide-co-D,L-lactide) bioresorbable implants.
Object. To evaluate the effectiveness of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with a bioresorbable implant, the authors conducted a prospective study of 43 patients with degenerative lumbar disc disease who underwent transforaminal lumbar interbody fusion. Methods. The authors used Infuse bone graft, which consisted of rhBMP-2 applied to an absorbable collagen sponge and contained within a HYDROSORB Telamon bioresorbable implant to perform the fusion. Multilevel fusions were performed in 30% of the 43 patients, for a total of 57 levels. At 6 months postoperatively, x-ray films and computerized tomography (CT) scans demonstrated solid fusion in 98% of 41 patients. Improvement from the baseline Oswestry Disability Rating was demonstrated at 6 months postoperatively in 68% of the patients, based on the Oswestry Disability Questionnaire. At 12 months all 11 patients in whom CT scans were obtained showed complete bridging of bone; there were no device-related complications. Conclusions. Results in this series provide evidence of the feasibility of using HYDROSORB Telamon bioresorbable spacers in combination with Infuse bone graft for lumbar spine fusion.
Lanman
Todd H
TH
DBA California Spine Group, and Century City Hospital, Los Angeles, California, USA. toddlanman@aol.com
Hopkins
Thomas J
TJ
D020341:Absorbable Implants; D000293:Adolescent; D000328:Adult; D000368:Aged; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D016025:Bone Transplantation; D003094:Collagen / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007403:Intervertebral Disc / Q000601:surgery; D007405:Intervertebral Disc Displacement / Q000175:diagnosis / Q000601:surgery / Q000628:therapy*; D007902:Length of Stay; D008159:Lumbar Vertebrae / Q000601:surgery*; D008297:Male; D008422:Materials Testing; D008875:Middle Aged; D009984:Orthopedic Fixation Devices; D016348:Osseointegration / Q000187:drug effects; D011091:Polyesters / Q000008:administration & dosage*; D011446:Prospective Studies; D011994:Recombinant Proteins; D013123:Spinal Fusion / Q000379:methods*; D016212:Transforming Growth Factor beta
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011091:Polyesters; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; C033616:poly(lactide); D003094:Collagen